Amyloid-β imaging with PET in Alzheimer's disease: is it feasible with current radiotracers and technologies?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed.

1. PET imaging utility of a novel Aβ-tracking PET radiotracer, [Journal of translational medicine · 2026
   Article
2. Multimodal neuroimaging insights into the neurobiology of healthy aging across the lifespan.European journal of nuclear medicine and molecular imaging · 2025
   Article
3. Assessing Mild Traumatic Brain Injury-Associated Blood-Brain Barrier (BBB) Damage and Restoration Using Late-Phase Perfusion Analysis by 3D ASL MRI: Implications for Predicting Progressive Brain Injury in a Focused Review.International journal of molecular sciences · 2024
   Review
4. A critical review of radiotracers in the positron emission tomography imaging of traumatic brain injury: FDG, tau, and amyloid imaging in mild traumatic brain injury and chronic traumatic encephalopathy.European journal of nuclear medicine and molecular imaging · 2021
   Review
5. A Cost-Consequence Analysis of Different Screening Procedures in Alzheimer's Disease: Results from the MOPEAD Project.Journal of Alzheimer's disease : JAD · 2021
   Article
6. Proven validity and management impact of amyloid imaging in Alzheimer's disease-repetita juvant.European journal of nuclear medicine and molecular imaging · 2020
   Article
7. Suboptimal validity of amyloid imaging-based diagnosis and management of Alzheimer's disease: why it is time to abandon the approach.European journal of nuclear medicine and molecular imaging · 2020
   Article
8. Dual targeting agents for Aβ plaque/P-glycoprotein and Aβ plaque/nicotinic acetylcholine α4β2* receptors-potential approaches to facilitate Aβ plaque removal in Alzheimer's disease brain.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2018
   Article
9. Amyloid-β positron emission tomography imaging probes: a critical review.Journal of Alzheimer's disease : JAD · 2013
   Review
10. Neuronuclear imaging in the evaluation of dementia and mild decline in cognition.Seminars in nuclear medicine · 2012
    Review
11. Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer's disease.European journal of nuclear medicine and molecular imaging · 2012
    Article
12. Multimodality Imaging Approaches in Alzheimer's disease. Part II: 1H MR spectroscopy, FDG PET and Amyloid PET.Dementia & neuropsychologia
    Review

Corrections and comments

• Commented on by
  Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer's disease.2012

Authors and funding

7 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as